Japan has begun deliberating insurance coverage for Amshepli, an iPS cell-derived product used to treat Parkinson's disease [1].
This move could make the world's first iPS cell regenerative medicine product accessible through public health insurance, significantly lowering the financial barrier for patients seeking advanced cellular therapy.
The Ministry of Health, Labour and Welfare presented a pricing proposal of approximately 55 million yen [1] for a single set consisting of 18 vials [1]. The proposal was introduced during a meeting of the Central Social Insurance Medical Council on April 8, 2026 [1].
Amshepli works by transplanting cells into the brains of Parkinson's patients to improve symptoms [3]. Because the treatment is highly specialized, the high cost reflects the complexity of producing iPS cell-derived therapies.
A spokesperson for the Ministry of Health, Labour and Welfare said that once insurance coverage is approved, the out-of-pocket cost for patients is expected to be reduced to 30 percent [3]. This shift aims to reduce the individual burden on patients while maintaining the sustainability of the public health system.
The product was developed by Sumitomo Pharma in coordination with the ministry [1]. While there are differing classifications regarding whether the product is a pharmaceutical or a regenerative medicine product, the current deliberations focus on its integration into the national reimbursement framework [3].
“The proposed price is approximately 55 million yen (18 vials per set).”
The integration of iPS cell therapies into Japan's public insurance system marks a transition from experimental clinical trials to standardized medical practice. While the 55 million yen price tag is steep, the 30 percent co-payment model prevents the treatment from being available only to the wealthy. This sets a global precedent for how governments may price and subsidize extremely high-cost regenerative medicines that offer potentially curative outcomes rather than lifelong symptom management.
